Navigation Links
Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
Date:11/23/2009

EMERYVILLE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that its board of directors has declared an extraordinary dividend of $0.18 per share of common stock, which will be paid on December 9, 2009 to stockholders of record as of November 30, 2009. The December 9, 2009 extraordinary dividend follows stockholder approval of the dissolution of NTI pursuant to a plan of complete liquidation and dissolution and an earlier extraordinary dividend of $0.75 per share that was paid to shareholders on November 18, 2009. The dividend of $0.18 per share was declared by the board of directors following the Company's recent sale of auction rate securities as disclosed in the Quarterly Report on Form 10-Q filed with the SEC on November 16, 2009.

NTI also announced plans to file a Form 25 with the Securities and Exchange Commission on December 7, 2009, to effect the voluntary delisting of NTI's common stock from the Nasdaq Capital Market. The Company expects this voluntary delisting from Nasdaq to become effective on December 17, 2009. NTI also expects to close its stock transfer books and to discontinue recording transfers and issuing stock certificates on December 17, 2009. Thereafter, NTI's stock may be traded in the OTC or Pink Sheet markets, but the Company will have no involvement in such trading. After December 17, 2009, the Company does not intend to issue press releases or file any reports with the SEC, except for Current Reports on Form 8-K describing material events related to its dissolution and liquidation. Also on December 17, 2009, the Company intends to file a certificate of dissolution in Delaware, its state of incorporation, after which the Company may not carry on any business except that appropriate to wind up and liquidate the business.

A detailed description of the dissolution process is contained in the definitive proxy statement filed with the SEC on September 22, 2009, a copy of which can be viewed on the SEC's website at www.sec.gov.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
4. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
5. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
6. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
7. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
8. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
9. Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies
10. Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing
11. Ionian Technologies, Inc. Receives Additional Funding from the Bill & Melinda Gates Foundation to Develop Point-of-Care Diagnostic Tests for the Developing World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):